Related Experiment Video
Updated: Sep 20, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
The Clinical and Epidemiologic Factors Associated with Mortality in Tuberculous Meningitis in Ceará State, Brazil
Luís Arthur Brasil Gadelha Farias1,2, Aldenise de Olinda Castro2, Marcos Maciel Sousa2
1Department of Infectious Diseases of Hospital das Clínicas, University of São Paulo, Laboratório de Investigação Médica - LIM 49, São Paulo, Brazil.
Abstract:
The aim of this study was to characterize and evaluate the risk factors for mortality in hospitalized patients with tuberculous meningitis (TBM). This was a retrospective study of hospitalized patients with TBM between 2016 and 2023 in Ceará State, Brazil. Generalized linear regression was performed to identify factors predictive of in-hospital mortality. The British Medical Research Council Severity (BMRCS) grading system for TBM was evaluated upon patient admission. Of the 94 patients with TBM enrolled in the study, the median age was 39.6 years, 86.7% were men, 81.2% were positive for HIV upon admission, 33.0% had prior tuberculosis, and 4.3% had multidrug-resistant infections. In-hospital mortality was 31.9% for all patients with a final diagnosis of TBM. When multivariable analysis was applied, significant associations with increased in-hospital mortality were seen among patients with BMRCS grade III (odds ratio [OR] 1.42; 95% CI 0.49-4.08), low hemoglobin levels (OR 6.44; 95% CI 0.59-70.27), low hematocrit levels (OR 0.53; 95% CI 0.04-5.97), higher aspartate aminotransferase (AST) levels (OR 1.98; 95% CI 0.67-5.77), and fewer cerebrospinal fluid (CSF) lymphocytes (OR 1.38; 95% CI 0.50-3.80) and decreased in-hospital mortality in those with orally administered rifampin, isoniazid, pyrazinamide, and ethambutol (RHZE) (OR 0.28; 95% CI 0.10-0.79). Mortality was higher among patients with BMRCS grade III, low hemoglobin levels, low hematocrit levels, higher AST, and fewer CSF lymphocytes, and lower in those orally administered RHZE.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Criteria for Causality: Bradford Hill Criteria - I

